Antabio
3 known investors
Find your way into Antabio
512 people in our graph share verified history with the Antabio team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows Magdalena Zalacain · together at SmithKline Beecham (overlapped)
×2knows the team · via Inserm
knows the team · via Duke University
×3knows the team · via SmithKline Beecham
×3knows the team · via Texas Instruments
×2knows the team · via Universidad Autonoma de Madrid
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.
Founders & leadership
ML
Marc LemonnierinChief Executive OfficerMarc Lemonnier is founding CEO of Antabio, a biopharmaceutical company developing treatments for drug-resistant bacterial infections. He has served as co-founder and board member of the BEAM Alliance, a European biotech consortium focused on antimicrobial resistance, and was a member of the Scientific Advisory Board of the Joint Programming Initiative on Antimicrobial Resistance.
RP
Rienk PypstraChief Medical Officer
GW
Gordon WaldroninChief Financial OfficerGordon Waldron has more than 30 years of experience in biotech, medtech, and high-tech sectors, with a background in M&A, financing, and business development including raising over €200M in venture capital and executing multiple exit transactions for biotech companies.
MZ
Magdalena ZalacaininChief Scientific OfficerMagdalena Zalacain is Chief Scientific Officer at Antabio and brings 25 years of experience in antibacterial drug discovery and development across the pharmaceutical industry, including expertise in target identification, lead optimization, and advancement of molecules through Phase I and II clinical studies. She has specialized in antibacterial discovery and antibiotic production and resistance in Streptomyces.
Investors · 3
In the news
Frequently asked questions
- What does Antabio do?
- Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.
- Who founded Antabio?
- Antabio was founded by Marc Lemonnier.
- Who are Antabio's investors?
- Antabio's investors include AMR Action Fund, BNP Paribas Développement, IRDI SORIDEC Gestion.